<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03646188</url>
  </required_header>
  <id_info>
    <org_study_id>SKNJCT-001</org_study_id>
    <nct_id>NCT03646188</nct_id>
  </id_info>
  <brief_title>Open-Label Dose Escalation Trial to Evaluate Dose Limiting Toxicity and Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in BCC</brief_title>
  <official_title>An Open-Label Dose Escalation Trial to Evaluate Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD), Safety, and Tolerability of Microneedle Arrays Containing Doxorubicin (D-MNA) in Participants With Basal Cell Carcinoma (BCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SkinJect, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SkinJect, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I study in participants with superficial or nodular Basal Cell Carcinoma
      (BCC), designed to assess dose limiting toxicities and maximum tolerated dose, efficacy,
      safety, and tolerability of dissolvable, tip-loaded, microneedle arrays containing
      doxorubicin (D-MNA). Doxorubicin is a cytotoxic anthracycline antibiotic and is currently
      approved for the treatment of a broad range of cancers, including but not limited to: breast,
      bladder, gastric, and ovarian cancers; small cell lung cancer; acute lymphoblastic leukemia;
      and acute myelo blastic leukemia. SkinJect, Inc. has developed a novel delivery system in the
      form of a tip-loaded dissolvable microneedle array (MNA) which will allow for topical
      delivery of doxorubicin directly to the lesion at concentrations that are far below standard
      systemic dosing, thereby reducing the adverse events associated with systemic delivery. The
      primary objective of this investigation is to establish the highest safe and tolerable dose
      of single applications of D-MNA, one application per week for three weeks in placebo, 25 µg,
      50 µg, 100 µg, and 200 µg dose groups in participants with BCC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>3+3 Design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT) and maximum tolerated dose (MTD)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Presence or absence of cutaneous reactions to the D-MNA application</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy as measured by histological analysis</measure>
    <time_frame>4 weeks</time_frame>
    <description>Histological confirmation of basal cell carcinoma eradication</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Basal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Placebo-containing MNA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 µg Doxorubicin-containing MNA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D-MNA's containing 25 µg of doxorubicin hydrochloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 µg Doxorubicin-containing MNA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D-MNA's containing 50 µg of doxorubicin hydrochloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 µg Doxorubicin-containing MNA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D-MNA's containing 100 µg of doxorubicin hydrochloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 µg Doxorubicin-containing MNA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D-MNA's containing 200 µg of doxorubicin hydrochloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-containing MNA</intervention_name>
    <description>A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering a placebo.</description>
    <arm_group_label>Placebo-containing MNA</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25 µg doxorubicin-containing MNA</intervention_name>
    <description>A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 25 µg of doxorubicin hydrochloride.</description>
    <arm_group_label>25 µg Doxorubicin-containing MNA</arm_group_label>
    <other_name>25 µg D-MNA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 µg doxorubicin-containing MNA</intervention_name>
    <description>A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 50 µg of doxorubicin hydrochloride.</description>
    <arm_group_label>50 µg Doxorubicin-containing MNA</arm_group_label>
    <other_name>50 µg D-MNA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 µg doxorubicin-containing MNA</intervention_name>
    <description>A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 100 µg of doxorubicin hydrochloride.</description>
    <arm_group_label>100 µg Doxorubicin-containing MNA</arm_group_label>
    <other_name>100 µg D-MNA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>200 µg doxorubicin-containing MNA</intervention_name>
    <description>A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 200 µg of doxorubicin hydrochloride.</description>
    <arm_group_label>200 µg Doxorubicin-containing MNA</arm_group_label>
    <other_name>200 µg D-MNA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult males and females, 40+ years in general good health as assessed by the
             investigator.

          2. BCC (subtype: superficial or nodular) confirmed histologically by diagnostic shave
             biopsy at the Screening Visit

          3. Primary BCC (i.e., no previous treatment)

          4. Lesion size ≥ 4 mm2 or 2 x 2 mm and ≤ 169 mm2 or 13 x 13 mm

          5. Participant must have no other &quot;clinically significant&quot; abnormal findings in his/her
             medical history, physical examination or clinical laboratory test results as assessed
             by the investigator

          6. Negative urine pregnancy at study entry for female of child bearing potential

          7. Men and women of child-producing potential must agree to use adequate contraception
             according to standard instructions by the investigator until the completion of the
             study

          8. Participant must to be willing to adhere to the instructions of the investigator and
             his or her research team

          9. Participant must sign an Informed Consent Form prior to any study specific procedures
             and entry into the study

        Exclusion Criteria:

          1. Evidence of clinically significant, unstable medical conditions as assessed by the
             investigator

          2. Excisional biopsy performed on the lesion to be treated in this study

          3. Recent therapy(ies) to the BCC treatment area

          4. Recurrent BCC (previously treated) at the site presented for treatment

          5. BCC lesion to be treated is located in an area where excisional biopsy is undesired or
             aesthetically unacceptable to the participant

          6. Previously demonstrated sensitivity to doxorubicin or carboxymethyl cellulose.

          7. Participant with other active malignancies with the exception of non-metastatic
             prostate cancer and carcinoma in situ of the skin and cervix

          8. Concomitant disease requiring systemic immunosuppressive treatment

          9. Genetic skin cancer disorder, e.g., basal cell nevus syndrome

         10. Participant is pregnant or breastfeeding

         11. Treatment with another investigational drug, device, or other intervention within 3
             months prior to the Screening Visit

         12. Existing condition or treatment within 3 months prior to the Screening Visit that may
             have impact on clinical outcome for the treatment of BCC or delay in wound healing
             from the elliptical excision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Suplick</last_name>
    <role>Study Director</role>
    <affiliation>InClinica, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael J Fare</last_name>
    <phone>2035332050</phone>
    <email>mfare@skinjectpatch.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Center for Clinical and Cosmetic Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Nestor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>August 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

